CHECKMATE PHARMACEUTICALS IN (CMPI) Stock Price, Quote, News and Overview
NASDAQ:CMPI - Nasdaq - US1628181083 - Common Stock
CMPI Quote, Performance and Key Statistics
NASDAQ:CMPI (5/27/2022, 8:00:01 PM)
10.5
+0.02 (+0.19%)
The current stock price of CMPI is 10.5 null. In the past month the price increased by 1.16%. In the past year, price increased by 55.33%.
CMPI Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.97 | 357.10B | ||
| AMGN | AMGEN INC | 15.29 | 162.72B | ||
| GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
| NTRA | NATERA INC | N/A | 21.43B | ||
| BIIB | BIOGEN INC | 8.54 | 20.49B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Related stock screener links
About CMPI
Company Profile
Checkmate Pharmaceuticals, Inc. is a clinical-stage biotechnology company. The company is headquartered in Cambridge, Massachusetts and currently employs 30 full-time employees. The company went IPO on 2020-08-07. The firm's product candidate, vidutolimod (CMP-001), is an advanced generation Toll-like receptor 9 (TLR9) agonist, delivered as a biologic virus-like particle (VLP) utilizing a CpG-A oligodeoxynucleotide as a key component, designed to trigger the body's innate immune system to attack tumors in combination with other therapies. The firm is conducting a Phase II trial of vidutolimod in combination with nivolumab (OPDIVO), in anti-PD-1 refractory melanoma. The firm is also conducting a randomized Phase II/III trial of vidutolimod in combination with nivolumab in first-line melanoma. The firm's VLP technology is designed to encapsulate and protect the CpG-A oligonucleotide from degradation in the tumor.
Company Info
CHECKMATE PHARMACEUTICALS IN
245 Main Street, 2Nd Floor
Cambridge MASSACHUSETTS 02142 US
CEO: Barry Labinger
Employees: 30
Company Website: http://checkmatepharma.com/
Phone: 19785032124.0
CHECKMATE PHARMACEUTICALS IN / CMPI FAQ
What is the stock price of CHECKMATE PHARMACEUTICALS IN today?
The current stock price of CMPI is 10.5 null. The price increased by 0.19% in the last trading session.
What is the ticker symbol for CHECKMATE PHARMACEUTICALS IN stock?
The exchange symbol of CHECKMATE PHARMACEUTICALS IN is CMPI and it is listed on the Nasdaq exchange.
On which exchange is CMPI stock listed?
CMPI stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for CHECKMATE PHARMACEUTICALS IN stock?
8 analysts have analysed CMPI and the average price target is 12.75 null. This implies a price increase of 21.43% is expected in the next year compared to the current price of 10.5. Check the CHECKMATE PHARMACEUTICALS IN stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is CHECKMATE PHARMACEUTICALS IN worth?
CHECKMATE PHARMACEUTICALS IN (CMPI) has a market capitalization of 231.40M null. This makes CMPI a Micro Cap stock.
How many employees does CHECKMATE PHARMACEUTICALS IN have?
CHECKMATE PHARMACEUTICALS IN (CMPI) currently has 30 employees.
What are the support and resistance levels for CHECKMATE PHARMACEUTICALS IN (CMPI) stock?
CHECKMATE PHARMACEUTICALS IN (CMPI) has a support level at 10.48 and a resistance level at 10.51. Check the full technical report for a detailed analysis of CMPI support and resistance levels.
Should I buy CHECKMATE PHARMACEUTICALS IN (CMPI) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of CMPI, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of CMPI, evaluating the profitability, health, valuation and growth aspects
- CHECKMATE PHARMACEUTICALS IN (CMPI) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- CHECKMATE PHARMACEUTICALS IN (CMPI) Sales and EPS estimates to see what analysts future expectations are.
- CHECKMATE PHARMACEUTICALS IN (CMPI) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- CHECKMATE PHARMACEUTICALS IN (CMPI) Insider and Institutional Ownership to learn about the owners and their transactions.
- CHECKMATE PHARMACEUTICALS IN (CMPI) Stock Chart to make your own analysis
- CHECKMATE PHARMACEUTICALS IN (CMPI) Latest news and press-releases to stay up to date.
Does CHECKMATE PHARMACEUTICALS IN (CMPI) stock pay dividends?
CMPI does not pay a dividend.
When does CHECKMATE PHARMACEUTICALS IN (CMPI) report earnings?
CHECKMATE PHARMACEUTICALS IN (CMPI) will report earnings on 2022-08-10.
What is the Price/Earnings (PE) ratio of CHECKMATE PHARMACEUTICALS IN (CMPI)?
CHECKMATE PHARMACEUTICALS IN (CMPI) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.92).
CMPI Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to CMPI. When comparing the yearly performance of all stocks, CMPI is one of the better performing stocks in the market, outperforming 99.74% of all stocks.
CMPI Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to CMPI. While CMPI seems to be doing ok healthwise, there are quite some concerns on its profitability.
CMPI Financial Highlights
Over the last trailing twelve months CMPI reported a non-GAAP Earnings per Share(EPS) of -2.92. The EPS increased by 69.23% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -94.34% | ||
| ROE | N/A | ||
| Debt/Equity | 0 |
CMPI Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 83% to CMPI. The Buy consensus is the average rating of analysts ratings from 8 analysts.